Overview

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Phase:
Phase 2
Details
Lead Sponsor:
Apellis Pharmaceuticals, Inc.